Baiaogeometry Raises A+ Round as A-Series Funding Tops $100M
AI-native biopharmaceutical company Baiaogeometry announced an A+ financing round led by Guoshou Capital, with Shanghai Biopharmaceutical Fund increasing its investment and other firms participating. According to 36氪, the company’s cumulative A-series funding now exceeds US$100 million. The proceeds are earmarked for iterating the GeoFlow molecular-level and GeoCell cell-level world models, expanding high-throughput automated laboratories, and commercializing its proprietary drug pipeline.
The financing provides substantial reported backing for Baiaogeometry’s AI world models, laboratory automation, and drug-pipeline commercialization, making it a notable AI-for-science funding event.
“百奥几何”完成完成1亿美元A轮系列融资-36氪
登录
搜索
#Baiaogeometry#GeoFlow#GeoCell#Guoshou Capital#Shanghai Biopharmaceutical Fund#CDB Sci-Tech#Ruili Investment#Guofang Venture Capital#Fortune Capital#Index Capital